Psychedelic medicines are rapidly gaining legitimacy on several fronts. As a psychedelic therapy developer, Compass Pathways (CMPS 1.02%) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment. But a lot of that risk burden could be alleviated soon, thanks to a pair of upcoming catalysts. If that happens, the stock has a high chance of skyrocketing. Let's take a moment to understand both of these two looming key events. This biotech's momentum ...